ATE391782T1 - Inhibitor-protein des wnt-signalwegs - Google Patents

Inhibitor-protein des wnt-signalwegs

Info

Publication number
ATE391782T1
ATE391782T1 AT98959767T AT98959767T ATE391782T1 AT E391782 T1 ATE391782 T1 AT E391782T1 AT 98959767 T AT98959767 T AT 98959767T AT 98959767 T AT98959767 T AT 98959767T AT E391782 T1 ATE391782 T1 AT E391782T1
Authority
AT
Austria
Prior art keywords
wnt signaling
signaling pathway
pathway inhibitor
inhibitor protein
transformants
Prior art date
Application number
AT98959767T
Other languages
German (de)
English (en)
Inventor
Christof Niehrs
Andrei Glinka
Original Assignee
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7846765&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE391782(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Deutsches Krebsforsch filed Critical Deutsches Krebsforsch
Application granted granted Critical
Publication of ATE391782T1 publication Critical patent/ATE391782T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98959767T 1997-10-27 1998-10-27 Inhibitor-protein des wnt-signalwegs ATE391782T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19747418A DE19747418C1 (de) 1997-10-27 1997-10-27 Inhibitor-Protein des wnt-Signalwegs

Publications (1)

Publication Number Publication Date
ATE391782T1 true ATE391782T1 (de) 2008-04-15

Family

ID=7846765

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98959767T ATE391782T1 (de) 1997-10-27 1998-10-27 Inhibitor-protein des wnt-signalwegs

Country Status (9)

Country Link
US (4) US6844422B1 (enExample)
EP (2) EP1923465A1 (enExample)
JP (1) JP2001520886A (enExample)
AT (1) ATE391782T1 (enExample)
DE (2) DE19747418C1 (enExample)
DK (1) DK1027440T3 (enExample)
ES (1) ES2306483T5 (enExample)
PT (1) PT1027440E (enExample)
WO (1) WO1999022000A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7057017B2 (en) 1997-04-16 2006-06-06 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
ATE505543T1 (de) * 1997-04-16 2011-04-15 Millennium Pharm Inc Zusammensetzung, umfassend einen antikörper, der selektiv an ein cysteinreiches sekretiertes protein (crsp) bindet
DE19747418C1 (de) 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US7446181B2 (en) * 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
US6344541B1 (en) 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
AU3510200A (en) * 1999-03-05 2000-09-21 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
JP2003501395A (ja) * 1999-06-08 2003-01-14 ローランティス・リミテッド 治療的使用
DE60101305D1 (de) * 2000-02-24 2004-01-08 Oxford Glycosciences Uk Ltd Dpi-6, ein therapeutischer biomarker in neurologischen krankheiten
EP1222933A1 (en) * 2001-01-15 2002-07-17 Academisch Ziekenhuis Leiden h.o.d.n., Leids Universitair Medisch Centrum Generation and/or reduction of new lung tissue in an affected lung, by modulation of the Wnt-pathway
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US7927597B2 (en) 2001-04-10 2011-04-19 Agensys, Inc. Methods to inhibit cell growth
US7713526B2 (en) * 2001-05-01 2010-05-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
US20040038860A1 (en) * 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
IL149404A0 (en) * 2002-04-29 2002-11-10 Yissum Res Dev Co METHODS AND COMPOSITIONS FOR MODULATING β-CATENIN PHOSPHORYLATION
CA2501235A1 (en) * 2002-10-04 2004-04-22 The Regents Of The University Of California Methods for treating cancer by inhibiting wnt signaling
US9046537B2 (en) 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
US8367822B2 (en) 2003-09-22 2013-02-05 Enzo Therapeutics, Inc. Compositions and methods for bone formation and remodeling
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US8637506B2 (en) * 2003-09-22 2014-01-28 Enzo Biochem, Inc. Compositions and methods for bone formation and remodeling
US7622553B2 (en) 2003-11-17 2009-11-24 Merck & Co., Inc. Rhesus monkey dickkopf-1, nucleotides encoding same, and uses thereof
WO2005049797A2 (en) 2003-11-17 2005-06-02 Merck & Co., Inc. Cynomolgus monkey dickkopf-4, nucleotides encoding same, and uses thereof
WO2005095448A2 (en) * 2004-03-23 2005-10-13 Oscient Pharmaceuticals Corporation Method of synthesizing and purifying dkk proteins and dkk proteins obtained thereby
US20060040883A1 (en) * 2004-05-14 2006-02-23 The Regents Of The University Of California Methods for treating cancer using anti-Wnt2 monoclonal antibodies and siRNA
US8343922B2 (en) * 2004-05-19 2013-01-01 Enzo Biochem, Inc. Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
US9052324B2 (en) 2004-05-19 2015-06-09 Enzo Biochem, Inc. Compounds and assays for controlling Wnt activity
US7618936B2 (en) * 2004-05-21 2009-11-17 The Regents Of The University Of California Methods for treating and diagnosing cancer with WNT inhibitory Factor-1 (WIF-1)
AU2005267722B2 (en) * 2004-08-04 2009-10-08 Amgen Inc. Antibodies to Dkk-1
NZ555216A (en) * 2004-11-10 2010-05-28 Hubrecht Lab Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation
WO2006061717A2 (en) * 2004-12-09 2006-06-15 Neuro Therapeutics Ab Materials and methods related to dickkopfs (dkk) and neurogenesis
EP1795198A1 (en) * 2005-12-09 2007-06-13 Hubrecht Laboratorium Treatment of Barret's esophagus
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
EP2121755A1 (en) * 2007-02-08 2009-11-25 Merck & Co., Inc. Antibodies specific for dkk-1
US20090074668A1 (en) * 2007-09-14 2009-03-19 Farjo Rafal A Vldlr-/- mouse models and related methods
AR075989A1 (es) 2009-04-10 2011-05-11 Lilly Co Eli Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria
US20120165270A1 (en) * 2009-04-27 2012-06-28 Yeon Sook Choi Inhibition of hair follicle growth by the wnt inhibitor dkk1
SA110310369B1 (ar) 2009-05-12 2014-09-02 Pfizer أجسام مضادة تخص dkk-1 واستخداماتها
US9133272B2 (en) 2011-03-01 2015-09-15 Amgen Inc. Bispecific binding agents
HUE039849T2 (hu) 2011-03-16 2019-02-28 Argenx Bvba CD70 elleni ellenanyagok
WO2013155447A1 (en) * 2012-04-13 2013-10-17 Children's Medical Center Corporation Tiki inhibitors
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133232A (en) * 1996-06-20 2000-10-17 The Regents Of The University Of California Endoderm, cardiac and neural inducing factors
WO1998027932A2 (en) 1996-12-20 1998-07-02 Human Genome Sciences, Inc. Cerebellum and embryo specific protein
ATE505543T1 (de) * 1997-04-16 2011-04-15 Millennium Pharm Inc Zusammensetzung, umfassend einen antikörper, der selektiv an ein cysteinreiches sekretiertes protein (crsp) bindet
US7057017B2 (en) * 1997-04-16 2006-06-06 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
DE19747418C1 (de) 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US7446181B2 (en) * 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins

Also Published As

Publication number Publication date
EP1923465A1 (de) 2008-05-21
EP1027440A1 (de) 2000-08-16
PT1027440E (pt) 2008-07-14
ES2306483T5 (es) 2012-03-16
US8536311B2 (en) 2013-09-17
WO1999022000A1 (de) 1999-05-06
US20050079173A1 (en) 2005-04-14
JP2001520886A (ja) 2001-11-06
US8461309B2 (en) 2013-06-11
DE59814214D1 (de) 2008-05-21
US20110118445A1 (en) 2011-05-19
EP1027440B2 (de) 2011-09-14
US20070077244A1 (en) 2007-04-05
EP1027440B1 (de) 2008-04-09
US6844422B1 (en) 2005-01-18
DE19747418C1 (de) 1999-07-15
ES2306483T3 (es) 2008-11-01
DK1027440T3 (da) 2008-08-04
US7138508B2 (en) 2006-11-21

Similar Documents

Publication Publication Date Title
ATE391782T1 (de) Inhibitor-protein des wnt-signalwegs
NO954722L (no) Peptid inhibitorer med urokinase reseptoraktivitet
FI965031A0 (fi) Sieni, jossa AreA-geeni on muunnettu, ja Aspergillus oryzaesta peräisin oleva areA-geeni
ATE195347T1 (de) Methoden der erhöhung der sekretion von überexpremierten proteinen
PT695360E (pt) Adenovirus recombinantes deficientes, para a terapia genica de tumores
ES8800051A1 (es) Un procedimiento para la preparacion de derivados de cetona electrofilicos activados de sustratos de peptidasa, utiles en la inhibicion de enzimas proteasas
ATE237342T1 (de) Inhibitoren der leukozytenadhäsion
AU7117496A (en) Peptide inhibitor for viral protease derived from the transframe region of the gag-pol gene
ES2145015T3 (es) Proteasas especificas de ubiquitina.
MY113489A (en) Reversible protease inhibitors
PT939628E (pt) Inibidores tiolsulfona de metaloproteases
ES2154629T3 (es) Mutantes t-pa resistentes a la inhibicion por sus inhibidores similares.
ES2153434T3 (es) Inhibidores de la proteasa del vih y sus intermedios.
NO974035L (no) En ny vekstfaktor og en genetisk sekvens som koder for denne
NO995531D0 (no) Nye mellomprodukter og fremgangsmåte for fremstilling derav
DE69629808D1 (de) Promtors für gen expression
MX9801190A (es) Inhibidores de prolil endopeptidasa.
CY1107776T1 (el) Νεα παραγωγα ολιγο-νουκλεοτιδιων για στοχευμενη αναστολη της εκφρασης γονιδιων
TR199601006A2 (tr) Engelleyici kappa proteinin (I,B) kesik formlari, rekombinant üretimi ve bunlarin kullanimi.
DK0652964T3 (da) Promotor af K. lactis transaldolasegenet og anvendelse heraf
ATE356212T1 (de) O-fukosyltransferase
DK0651811T3 (da) Promotor fra ribosomproteingenet RP28 af K. Lactis og anvendelse deraf
DE69613685D1 (de) D-aminosäure-oxidase kodierendes dns-fragment
WO2004052929A3 (en) Recombinant cell line
DK0640139T3 (da) Fremgangsmåde til fremstilling af rekombinante proteiner i streptomyces